Literature DB >> 80402

Tallysomycin, a new antitumor antibiotic complex related to bleomycin. III. Antitumor activity of tallysomycins A and B.

H Imanishi, M Ohbayashi, Y Nishiyama, H Kawaguchi.   

Abstract

The antitumor activity of tallysomycins A and B was determined in five experimental tumor systems in mice. Tallysomycins A and B were highly active against B16 melanoma, sarcoma 180 ascites tumor and Lewis lung carcinoma, and moderately active against P388 leukemia but were without effect on lymphoid leukemia L1210. The antitumor activity of tallysomycin A was 2 to 3 times that of tallysomycin B and 3 to 17 times that of bleomycin. Tallysomycin A was about 1.5 and 4 times more toxic for mice than tallysomycin B and bleomycin, respectively, in terms of subacute LD50 values.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 80402     DOI: 10.7164/antibiotics.31.667

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  2 in total

1.  Phase I trial of tallysomycin S10b, a bleomycin analogue.

Authors:  F P Paolozzi; R C Gaver; N B Newman; B J Poiesz; S DeFino; A Louie; R L Comis
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

2.  Tallysomycin S10b: experimental antitumor activity and toxicity.

Authors:  J E Schurig; W C Rose; R S Hirth; A Schlein; J B Huftalen; A P Florczyk; W T Bradner
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.